GILDGilead SciencesRunning, no new patients
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
Advanced Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 400 (planned)
- Started
- Feb 21, 2023
- Main results expected
- Dec 2027
- Fully finished
- Dec 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Measured over: Up to 58 months
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Measured over: Up to 58 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05676931 · record last updated 2026-06-01 · checked 2026-11-09 15:47 UTC